Richlink Invested 4D Medical’s Lung Imaging Technology Receives FDA Clearance as COVID-19

4DMedical, Richlink Venture Captial Fund invested Australian medical technology company specializing in medical imaging innovation software, announced it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™, a patented four-dimensional lung imaging process that rapidly and automatically analyses any functional lung impairment from a single X-ray. 4DMedical’s U.S. operations are based in Woodland Hills, California.

Original article: